Investigation launched into allegations of false information and share-price manipulation
- Sanofi under preliminary probe in France for possible market manipulation
- Investigation opened by French Financial Prosecutor’s Office
- Allegations relate to launch of anti-inflammatory drug Dupixent
- Sanofi denies awareness of investigation
- Sanofi expects Dupixent revenue to reach EUR13 billion in 2024
- Sanofi shares down 1.5% in response to news
France’s financial prosecutors have opened a preliminary investigation into Sanofi over possible dissemination of false or misleading information and share-price manipulation. The investigation, opened by the French Financial Prosecutor’s Office in March, focuses on allegations related to the launch of Sanofi’s anti-inflammatory drug Dupixent. Sanofi has denied any awareness of the investigation and expects Dupixent revenue to reach EUR13 billion in 2024. In response to the news, Sanofi shares were down 1.5%.
Factuality Level: 7
Factuality Justification: The article provides information about a preliminary investigation into Sanofi by France’s financial prosecutors. It includes statements from both Sanofi and Regeneron, as well as details about the allegations and the financial impact on Sanofi. However, the article lacks specific details about the nature of the allegations and the progress of the investigation, which could affect the overall factuality level.
Noise Level: 3
Noise Justification: The article provides a brief overview of the preliminary investigation into Sanofi over possible dissemination of false or misleading information and share-price manipulation. It includes statements from Sanofi and Regeneron, as well as some financial data. However, it lacks in-depth analysis, evidence, and actionable insights.
Financial Relevance: Yes
Financial Markets Impacted: Sanofi
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to a financial company, Sanofi, and the investigation into possible dissemination of false or misleading information and share-price manipulation. However, there is no mention of an extreme event or its impact.
Public Companies: Sanofi (SNY), Regeneron Pharmaceuticals (REGN)
Key People:
Reported publicly:
www.marketwatch.com 
